Brian Cheng
Stock Analyst at JP Morgan
(1.01)
# 3,051
Out of 4,667 analysts
56
Total ratings
34.29%
Success rate
-21.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Initiates: Overweight | $126 | $94.81 | +32.90% | 1 | Nov 14, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $23.72 | +18.04% | 4 | Nov 7, 2024 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $27 → $24 | $7.85 | +205.73% | 2 | Aug 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $61 → $55 | $13.12 | +319.21% | 3 | Aug 12, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $51 → $46 | $26.17 | +75.77% | 2 | Aug 8, 2024 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $39 → $33 | $4.12 | +700.97% | 2 | Jul 31, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $39 → $48 | $40.65 | +18.08% | 3 | Jul 25, 2024 | |
| MGX Metagenomi | Downgrades: Neutral | $16 → $6 | $1.65 | +263.64% | 2 | May 2, 2024 | |
| IMNM Immunome | Initiates: Overweight | $24 | $9.33 | +157.23% | 2 | Apr 30, 2024 | |
| PGEN Precigen | Downgrades: Underweight | n/a | $0.84 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $2.22 | +125.23% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $2.05 | +290.24% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $2.41 | +273.44% | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $15.82 | +45.39% | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.49 | +30.55% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $1.48 | +845.95% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.98 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.97 | +520.41% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $14.55 | -38.14% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.12 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.70 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.72 | +782.35% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.40 | +1,328.57% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $16.17 | +425.66% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.30 | +187.67% | 1 | Aug 3, 2021 |
Blueprint Medicines
Nov 14, 2024
Initiates: Overweight
Price Target: $126
Current: $94.81
Upside: +32.90%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $23.72
Upside: +18.04%
iTeos Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $27 → $24
Current: $7.85
Upside: +205.73%
Intellia Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $61 → $55
Current: $13.12
Upside: +319.21%
Immunovant
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $26.17
Upside: +75.77%
Kyverna Therapeutics
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $4.12
Upside: +700.97%
Protagonist Therapeutics
Jul 25, 2024
Maintains: Overweight
Price Target: $39 → $48
Current: $40.65
Upside: +18.08%
Metagenomi
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.65
Upside: +263.64%
Immunome
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $9.33
Upside: +157.23%
Precigen
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.84
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $2.22
Upside: +125.23%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $2.05
Upside: +290.24%
Feb 27, 2024
Maintains: Neutral
Price Target: $8 → $9
Current: $2.41
Upside: +273.44%
Dec 5, 2023
Initiates: Overweight
Price Target: $23
Current: $15.82
Upside: +45.39%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.49
Upside: +30.55%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $1.48
Upside: +845.95%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $1.98
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.97
Upside: +520.41%
Mar 31, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $14.55
Upside: -38.14%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.12
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.70
Upside: -
Jan 7, 2022
Initiates: Overweight
Price Target: $24
Current: $2.72
Upside: +782.35%
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $1.40
Upside: +1,328.57%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $16.17
Upside: +425.66%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.30
Upside: +187.67%